Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 428

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 428
---
 technologies or duplicate any of our technologies without 
 infringing our intellectual property rights;                                                                      |

| • |     | it is possible that the pending patent applications we own or license will not lead to issued patents; |

- 290 -

| • |     | issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by 
 our competitors;                                                                                               |

| • |     | our competitors might conduct research and development activities in countries where we do not have patent rights                   
 and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; |

| • |     | we may not develop additional proprietary technologies that are patentable; |

| • |     | the patents of others may have an adverse effect on our business; and |

| • |     | we may choose not to file a patent in order to maintain certain trade secrets or                
 know-how, and a third party may subsequently file a patent covering such intellectual property. |

Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. Our commercial success depends in part on avoiding infringement or misappropriation of the patents, intellectual property and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our products or products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or corresponding foreign patent offices. Numerous third-party United States and foreign issued patents and pending patent applications exist in the fields in which we are developing products or product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product or product candidates.